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Abstract
Stress and anxiety disorders are risk factors for depression and these behaviours are modulated by 
corticotropin releasing factor (CRFR1) and serotonin (5-HT2R) receptors. However, the potential 
behavioral and cellular interaction between these two receptors is unclear. Here, we showed that 
pre-administration of CRF into the prefrontal cortex of mice sensitized 5-HT2R-mediated anxiety 
behaviours in response to 2,5-dimethoxy-4-iodoamphetamine. In both heterologous cell cultures 
and mouse cortical neurons, the activation of CRFR1 also sensitized 5-HT2 receptor-mediated 
inositol phosphate formation. CRFR1-mediated increases in 5-HT2R signaling were dependent 
upon receptor internalization and receptor recycling via rapid recycling endosomes resulting in 
increased cell surface 5-HT2R expression. The sensitization of 5-HT2R signaling by CRFR1 
required intact PDZ domain binding motifs at the end of the C-terminal tails of both receptor 
types. These data reveal a novel mechanism by which CRF, a peptide known to be released by 
stress, sensitized anxiety-related behaviour via sensitization of 5-HT2R signaling.
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Anxiety and major depressive disorder often present as co-morbid disorders and the 
expression and severity of these disorders is commonly associated with stressful 
experiences1. In response to stress, corticotropin releasing factor (CRF) regulates the activity 
of hypothalamic-pituitary-adrenal (HPA) axis and triggers changes in other 
neurotransmitters systems, such as serotonin (5-HT)2-6. CRF is also known to influence 
anxiety responses and CRF receptor 1 (CRFR1) may be particularly important in this 
regard7-9. 5-HT also has diverse functional effects in the central nervous system, as well as 
in the periphery and plays an important role in modulating depression and anxiety-related 
behaviours in humans and rodents10,11. In particular, pharmacological studies and knockout 
mice have demonstrated that 5-HT2A and 5-HT2C receptors contribute to anxiety and are 
pharmacological targets for the treatment of anxiety2,12-17. The targeted deletion of either 
the 5-HT2AR, 5-HT2CR or CRFR1 in mice is also associated with a reduction in anxiety-
related behaviour12,13,18. However, little is known about the molecular mechanisms 
underlying the cross talk between these two important neurotransmitter systems at the 
cellular level.
CRF is a 41 amino acid peptide that activates the HPA axis to regulate adrenocorticotropin 
secretion by the pituitary gland in response to acute and chronic stress19,20. CRF peptide 
acts through two subtypes of Gs-coupled G protein-coupled receptors (GPCRs) resulting in 
increased intracellular cAMP formation21,22. Besides its endocrine function in the pituitary, 
CRF is also involved in a wide variety of effects not related to its pituitary activity 
indicating it also functions as either a neurotransmitter or neuromodulator in the brain. 
Consistent with its role as a neurotransmitter, CRF immunoreactive terminals, CRF binding 
sites and CRF receptor mRNA are widely distributed in areas of the brain that are unrelated 
to endocrine function23-25. There are also fifteen genes encoding functional serotonin 
receptors (5-HTR) in the mammalian brain that are classified into 7 families (5-HT1 to 5-
HT7), all of which are GPCRs except for 5-HT3Rs which are ionotropic receptors26.
The 5-HT2 and CRF receptors each contribute to the regulation of anxiety behaviors and 
stress responses and CRF treatment is demonstrated to prolong 5-HT regulation of 
GABAergic inhibitory transmission27. The molecular and cellular basis for the action of 
CRF on 5-HT signaling remains unknown, as agents that increase cAMP accumulation do 
not mimic the effect of CRFR activation27. Therefore, in the present study we tested the 
hypothesis that CRFR1 activation would increase 5-HT2R-mediated signal transduction. In 
addition to the well characterized mechanism by which CRF can stimulate 5-HT release 
from serotonergic neurons to modulate anxiety6,7, we report that CRFR1 activation 
sensitized 5-HT2 receptor signaling by promoting the recruitment of constitutively 
internalized 5-HT2 receptor to the cell surface. This new mechanism of 5-HT2R regulation 
was physiologically relevant as the pre-administration of CRF into the prefrontal cortex of 
mice significantly enhanced subsequent 5-HT2 receptor-stimulated anxiety-related 
behaviour. This effect was blocked by a 5-HT2A receptor-selective antagonist. Taken 
together, our data provide a novel mechanism by which CRFR1 endocytosis and recycling 
can sensitize 5-HT2R-mediated signaling and anxiety-related behaviours.
Magalhaes et al. Page 2














CRFR1 activation enhances 5-HT2R signaling
The signaling of both 5-HT2A/C and CRF receptors is linked to the regulation of anxiety 
behaviors and CRFR activation has previously been shown to modulate 5-HT2R signaling 
by an unknown mechanism27. Therefore, we examined the mechanism by which CRFR1, a 
receptor coupled Gαs-stimulated cAMP accumulation, might alter the signaling of Gαq/11-
coupled receptors (5-HT2AR and 5-HT2CR) that stimulate increases in inositol phosphate 
formation. In our initial studies, we utilized human embryonic kidney (HEK 293) cells that 
do not express endogenous CRFR1 or 5-HT2Rs to examine whether CRFR1 activation 
altered 5-HT2R signaling. In HEK 293 cells transfected to express either 5-HT2AR or 5-
HT2CR in the absence of CRFR1, the treatment of cells with increasing concentrations of 5-
HT resulted in a dose-dependent increase in inositol phosphate formation and pretreatment 
with CRF had no effect on the dose-response curves for inositol phosphate formation for 
either receptor (Fig. 1a, Supplementary Table 1). However, in cells expressing either 5-
HT2AR or 5-HT2CR along with CRFR1, CRF pretreatment (500 nM) for 30 min increased 
the maximum efficacy (EMAX) for both 5-HT2AR- and 5-HT2CR-stimulated inositol 
phosphate formation by 40 ± 4.7% and 47 ± 5.5%, respectively (Fig. 1b,c, Supplementary 
Table 1). The increase in 5-HT2R-mediated inositol phosphate formation observed following 
CRF pretreatment was not attributable to CRFR1-mediated inositol phosphate formation, as 
CRF treatment of HEK 293 cells for 30 min did not result in inositol phosphate formation in 
cells expressing the 5-HT2CR alone, CRFR1 alone or expressing both receptors (Fig. 1d, 
Supplementary Table 1). To determine whether the observed enhancement in 5-HT2R 
signaling was specific to CRFR1, we examined whether the coexpression and activation of 
another Gαs-coupled GPCR also increased 5-HT2R signaling. However, in HEK 293 cells 
expressing both the β2-adrenergic receptor (β2AR) and 5-HT2AR, isoproterenol (100 μM) 
pretreatment had no effect on the magnitude of 5-HT2AR-stimulated inositol phosphate 
responses (Fig. 1e, Supplementary Table 1). Similarly, in cells co-expressing CRFR2 and 5-
HT2AR, CRF pretreatment did not increase 5-HT2AR-stimulated inositol phosphate 
responses (Fig. 1f, Supplementary Table 1). When we examined whether the activation of 
the 5-HT2AR might increase CRFR1-mediated cAMP formation, we found that 5-HT (10 
μM) pretreatment had no effect on CRFR1 responsiveness (Fig. 1g). In addition, we 
examined the effect of inhibiting either cAMP-dependent protein kinase (PKA) or protein 
kinase C (PKC) that are activated by CRFR1 and 5-HT2R, respectively and found that 
inhibition of either kinase had no effect on CRFR1-mediated increases in 5-HT2CR 
signaling (Supplementary Fig. 1). Thus, CRFR1 activation lead to increased 5-HT2R 
signaling and this increased 5-HT2R signaling was unique to CRFR1 and could not be 
mimicked by another Gαs-coupled GPCR.
It was essential to establish whether the augmented 5-HT2R signaling in response to CRF 
was observed in prefrontal cortical neurons. Therefore, we first examined whether both 
receptors were expressed in neurons from the prefrontal cortex of mice. Mouse prefrontal 
cortical slices were stained with polyclonal antibodies that recognized either endogenous 5-
HT2AR or CRFR1 (Fig. 2a,b) and Hoechst (Fig. 2c) to mark cell nuclei. We found that a 
subpopulation of neurons in the prefrontal cortex stained positive for both 5-HT2AR and 
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CRFR1 protein (Fig. 2d,e). The specificity of the 5-HT2AR antibody was confirmed in 
parallel Western blot and immunofluorescent studies of prefrontal cortex from 5-HT2AR 
knockout mice. CRFR1 antibody specificity was confirmed in HEK293 cells expressing 
HA-CRFR1 (Supplementary Data Fig. 2).
We next found that CRF (500 nM) pretreatment of mouse neuronal cultures for 30 min 
significantly increased 5-HT (50 μM)-stimulated [3H]-myo-inositol conversion to inositol 
phosphate. Importantly, in slices prepared from prefrontal cortex CRF pretreatment 
increased 5-HT-stimulated inositol phosphate formation by 2.3 ± 0.2 fold and when the 5-
HT2A/CR selective agonist 2,5-dimethoxy-4-iodoamphetamine (DOI; 10 μM) was used, 
CRF pretreatment increased inositol phosphate formation by 1.5 ± 0.2 fold. Thus, consistent 
with what we observed in an overexpression system the pretreatment of endogenous CRF 
receptor increased 5-HT/DOI-stimulated inositol phosphate formation in prefrontal neuronal 
cultures and tissue.
Mechanism underlying CRF-mediated increases in 5-HT2R signaling
The sensitization in 5-HT2R signaling was unique to CRFR1 and was independent of the 
activity of second messenger-dependent protein kinases activated by either receptor 
(Supplementary Fig. 1). Therefore, we examined whether agonist-stimulated CRFR1 
internalization contributed to the sensitization of 5-HT2R signaling. First, we tested whether 
the expression of a dominant-negative inhibitor of clathrin-mediated endocytosis (dynamin 
I-K44A) altered CRFR1-mediated increases in 5-HT2AR signaling in HEK 293 cells. We 
found that dynamin I-K44A expression completely eliminated CRFR1-dependent increases 
in 5-HT2AR-stimulated inositol phosphate formation following CRF pretreatment (Fig. 3a). 
Previous studies have demonstrated that CRFR1, 5-HT2AR and 5-HT2CR are 
internalized28,29. Therefore, we examined the localization of HA-epitope tagged CRFR1 and 
FLAG-epitope tagged 5-HT2R that were immunofluorescently labeled at the cell surface at 
4°C and then allowed to warm to 37°C in both HEK 293 cells and rat cortical neurons. We 
found that both FLAG-5-HT2AR (Fig. 3b) and FLAG-5-HT2CR (Fig. 3c) were internalized 
from the cell surface in the absence of agonist, whereas no constitutive endocytosis was 
observed for the HA-CRFR1 (Fig. 3b,c). Similarly, in transfected neurons FLAG-5-HT2AR, 
but not CRFR1 was observed to internalize from the cell surface in the absence of agonist 
treatment (Fig. 3d). In contrast, when rat cortical neurons were warmed to 37°C and treated 
with 100 nM CRF both HA-CRFR1 and FLAG-5-HT2AR (untreated) were endocytosed and 
were colocalized within the same intracellular vesicles (Fig. 3e). Similar to what was 
observed for the HA-CRFR1, agonist-stimulated HA-β2AR also colocalized with FLAG-5-
HT2AR in vesicles after isoproterenol treatment (Fig. 3f), but this does not translate into an 
alteration in 5-HT2AR signaling (Fig. 1e). We also found that HA-CRFR1 and FLAG-5-
HT2AR were colocalized to both Rab5- and Rab4-positive endocytic organelles 
(Supplemental Data Fig. 3). Thus, not only was the localization of the 5-HT2R between the 
cell surface and intracellular compartments of cell dynamically regulated, CRFR1 
endocytosis was required for the sensitization of 5-HT2R responses to agonist.
To further assess the role of the intracellular trafficking of both the 5-HT2AR and CRFR1 in 
the CRF-dependent regulation of 5-HT2AR signaling, we examined whether the inhibition of 
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receptor recycling with monensin would block CRF-mediated increases in 5-HT2AR 
signaling. Treatment of cells with 100 μM monensin did not affect 5-HT2AR signaling in the 
absence of CRF pretreatment (Fig. 4a). However, monensin treatment attenuated the 
increase in 5-HT2AR signaling observed following CRF pretreatment (Fig. 4a). To assess 
whether the effect of monensin treatment was related to the recycling of receptors through 
endosomes, we utilized dominant negative Rab4-S28N and Rab11-S25N proteins to 
selectively inhibit receptor recycling via rapid (Rab4 positive) and slow (Rab11 positive) 
recycling endosomes. We found that the overexpression of Rab4-S28N, but not the 
overexpression of Rab11-S25N, blocked the increase in 5-HT2AR-mediated inositol 
phosphate formation induced by CRFR1 pre-activation (Fig. 4b,c). Biotinylation of cell 
surface FLAG-5-HT2AR also revealed that CRF pretreatment increased the cell surface 
expression of the 5-HT2AR by 3.7 ±1.8 fold (Fig. 4d). Accordingly, the endocytosis and 
recycling of CRFR1 was essential for regulating 5-HT2AR signaling via mechanism that 
resulted in increased 5-HT2AR expression at the cell surface.
All three receptors encoded class I PDZ domain interacting motifs at the end of their 
carboxyl-terminal tails and both the 5-HT2AR and 5-HT2cR were previously demonstrated to 
interact with PDZ domain containing proteins that regulate receptor trafficking30-34. 
Therefore, we examined whether the deletion of three amino acids from the 5-HT2AR 
(ΔSCV) and CRFR1 (ΔTAV) carboxyl-terminal tails would affect cell surface recruitment of 
the 5-HT2AR following CRF treatment. When tested, we found that the deletion of either the 
5-HT2AR or CRFR1 PDZ domain binding motifs attenuated the CRF-dependent increases in 
5-HT2AR at the cell surface (Fig. 5a). Since a loss of the PDZ binding motifs on either the 5-
HT2AR or CRFR1 resulted in a loss of CRFR1-dependent recruitment of 5-HT2AR to the 
cell surface, we tested whether PDZ domain interactions were required for CRFR1-mediated 
sensitization of 5-HT2R signaling. Truncation of the final three amino acid residues of the 
CRFR1 carboxyl terminal tail (ΔTAV) prevented CRFR1-mediated increases in 5-HT2CR 
signaling following CRF pretreatment (Fig. 5b). Similarly, increased 5-HT2cR inositol 
phosphate formation in response to CRFR1 activation was not observed following the 
deletion of either the deletion of either the 5-HT2CR PDZ (ΔSSV) or 5-HT2AR (ΔSCV) 
domain binding motifs (Fig. 5c,d). We also found that the treatment of HEK293 cells with a 
peptide that encoded the HIV Tat protein membrane transducing domain fused to the last 10 
amino acid residues corresponding to the CRFR1 carboxyl-terminal tail prevented CRFR1-
mediated sensitization of 5-HT2AR signaling (Fig. 5e). Thus, intact PDZ domain protein 
interactions with both receptors were required for CRFR1-dependent sensitization of 5-
HT2R responses.
CRF treatment enhances 5-HT-mediated anxiety-related behaviours
To assess the role of CRF in the regulation of 5-HT2R-mediated anxiety behaviour, two 
anxiety-related behaviours were examined in mice: (1) the latency for mice to enter the 
center of an open field and (2) the latency for mice to enter the open arm of an elevated plus 
maze. Having established the molecular mechanism by which CRFR1 activation sensitized 
5-HT2R responses in vitro, we examined whether the infusion of CRF peptide (1.5 μg) into 
the medial prefrontal cortex followed by the intraperitoneal administration of the 5-HT2R 
selective agonist DOI (0.15 mg/kg) would sensitize 5-HT-mediated anxiety-related 
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behavioral responses. The latency of mice to enter the center of an open field varied as a 
function of the intracerebral infusion (CRF vs vehicle) x systemic challenge (DOI vs 
vehicle) interaction, F(1,35)=7.01, p < 0.01. Follow-up analysis of the mean latencies for 
mice to enter the center square in a 5 min open field test revealed that neither the CRF nor 
the DOI treatments alone influenced performance relative to the vehicle-vehicle condition 
(Fig. 6a). However, among mice that received both CRF and DOI treatment the latency to 
enter the central portion of the maze was significantly longer than that of mice that received 
only a single drug treatment or vehicle (Fig. 6a). In the plus-maze test, the latency to enter 
an open arm, as well as the number of entries onto the open arms, also varied as a function 
of the IC infusion (CRF vs vehicle) x systemic challenge (DOI vs vehicle) interaction, 
F(1,35) = 7.85, 3.89, p < 0.01 and 0.05, respectively. Follow-up comparisons indicated that 
DOI itself produced a modest reduction in the latency to enter an open arm (p < 0.08) and 
the number of arm entries emitted (p < 0.10), whereas CRF infusion had no effect (Fig. 
6b,c). However, among mice that received both the CRF and DOI treatments a marked 
increase of the open arm latency and a decreased frequency of open arm entries was evident 
relative to mice that received either treatment alone (Fig. 6b,c). In contrast to these findings, 
the number of entries into the closed arms, which approximately doubled the open arm 
entries, did not vary with either the CRF or DOI treatments, or as a function of their 
interaction (p > .15) (Fig. 6d). Likewise, the time spent in the closed arms did not vary as a 
function of the treatments mice received (F < 1) (Fig. 6e).
In a follow up series of experiments we examined whether the synergistic effects of DOI and 
CRF treatment could be antagonized by the pretreatment of mice with the 5-HT2AR 
selective antagonist M100907. We found that the latencies to enter the open arms of the plus 
maze varied as a function of the DOI x CRF x M100907 interaction, F(1,41) = 6.00, p = 
0.018 (Fig. 7a). The tests confirmed that treatment with DOI alone did not influence the 
latencies to enter the open arms, whereas CRF infusion provoked a moderate, but 
statistically significant increase in response latencies. In mice that received the combination 
of systemic DOI following CRF administration to the prefrontal cortex, latencies to enter the 
open arms were still longer (Fig. 7a). When mice were treated with M100907 alone or with 
M100907 plus DOI none of the mice entered the open arms of the plus maze. Likewise, 
when given M100907 in conjunction with CRF, latencies were longer than in mice that 
received CRF alone, although several mice did enter onto the open arms (Fig. 7a). As 
predicted, when mice received M100907 in conjunction with DOI and CRF the latencies to 
enter the open arms of the maze were markedly reduced from that elicited by the 
combination of DOI plus CRF. Thus despite the fact that M100907-treated mice displayed a 
significant reluctance to enter the open arms of the maze, M100907 effectively attenuated 
the effects of the DOI-CRF combination.
The analysis of both the number of open-arm entries and the time spent in the open arms 
revealed responses which paralleled that of the response latencies (Fig. 7b,c). Specifically, 
the DOI x CRF x M100907 interaction was highly significant, F(1,41) = 10.78, 15.04, p < 
0.001, and the follow up tests confirmed that neither CRF nor DOI alone affected the 
frequency of open arm entries. By contrast the combination of these treatments significantly 
reduced open arm entries and reduced the time spent in the open arms, as observed in the 
preceding studies. The M100907 profoundly influenced the frequency of open arm entries 
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and time spent on the open arms (as described in the analysis of the latencies) in that mice 
treated with the compound (alone or in combination with DOI) did not make any entries 
onto the open arm, and most animals treated with M100907 and CRF also failed to make 
open arm entries (Fig. 7b,c). However, when animals received all three compounds, open 
arm entries and time on the open arms increased significantly relative to mice that either 
received DOI and CRF (but not M100907) or those that received CRF and M100907 (but 
not DOI). However, the number of entries were clearly fewer than that of animals that were 
either untreated or that had received only DOI (Fig. 7b).
The analysis of the entries to the closed arms indicated that behavior was significantly 
influenced by the DOI x CRF x M100907 interaction, F(1,41) = 9.29, p < 0.01 (Fig. 7d). The 
follow up tests indicated that DOI, CRF and the combination of these treatments increased 
closed arm entries relative to mice that had received only the vehicle treatments. Thus, one 
cannot ascribe the reduced open arm entries induced by the CRF-DOI combination to 
reduced motor activity. The M100907 treatment alone reduced the frequency of arm entries, 
irrespective of the other treatments received, although the magnitude of this effect was less 
pronounced in mice that had also received DOI + CRF. The time spent in the closed arms 
was unaffected by either the DOI or CRF or their combination (Fig. 7e). However, time 
spent in the closed arms was increased by M100907 in those mice that received this 
treatment alone, or either DOI or CRF. However, time spent in the closed arms among mice 
that received the combination of the three treatments did not differ from that of mice that 
received the CRF + DOI or those that received DOI + M100907. However, the time spent in 
the closed arms among mice that received the combination of DOI, CRF and M100907 was 
indistinguishable from that of mice that received only vehicle, or either CRF or DOI alone 
(Fig. 7e). Taken together our data in mice showed that CRFR activation resulted in 
increased 5-HT2R signaling in vivo and that the activation of both receptors had an 
important effect on behavioural responses associated with anxiety.
DISCUSSION
We demonstrated here that CRF acted through CRFR1 to sensitize 5-HT2R-mediated 
signaling and anxiety behaviours thereby linking CRF-mediated stress responses to anxiety 
and depression. Our findings indicated that enhanced 5-HT2R sensitivity following CRF 
pretreatment in vivo as evidenced by increased anxiety-related behaviour in mice. This 
observation showed that CRF could potentiate 5HT2R mediated behaviours and has 
implications regarding the mechanisms by which stressors may exacerbate the anxiogenic 
effects of 5HT2R activation. Importantly, our behavioural data, which showed a functional 
interaction between CRF and 5-HT, were supported at the cellular level. Thus, we 
demonstrated both that CRFR1 activation positively modulated 5-HT2R signaling in cortical 
neurons and that these two receptors were co-expressed in the same neuronal populations. 
The molecular mechanism underlying the sensitization of 5-HT2R signaling by CRFR1 
required agonist-stimulated CRFR1 endocytosis and recycling which resulted in increased 
cell surface expression of 5-HT2Rs and increased second messenger responses to 5-HT 
treatment (Supplemental Data Fig. 4). These findings provide an additional mechanism by 
which receptor endocytosis and recycling contribute to the regulation of GPCR 
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responsiveness in general and specifically show how CRFR1 activation can positively 
modulate 5-HT2R signaling thereby leading to pathophysiological behavioural responses.
We observed that anxiety responses in both an open field emergence and in a plus-maze test 
were sensitized in mice that were pretreated with CRF administered to the prefrontal cortex, 
followed by systemic administration of a low dose of DOI. When administered alone, 
neither of these treatments affected performance in these tests, demonstrating that the CRF 
and DOI treatments acted synergistically to provoke the anxiety responses. The behavioral 
change could not be attributed to diminished motoric activity, as entries into the closed arms 
of the plus-maze were unaffected by the treatments. It should be said that when significantly 
higher doses of DOI were employed (0.625 and 1.25; data not shown) elevated arm entries 
were evident (as opposed to reduced open-arm entries), likely reflecting an overall arousal. 
It has been reported that CRF influences anxiety processes, and that CRFR1 may be 
especially relevant in this regard7-9. Likewise, pharmacological studies have pointed to the 
involvement of 5-HT manipulations in attenuating anxiety and that 5-HT2AR and 5-HT2CR 
may contribute to CRF-mediated anxiety22,11,15,16. Thus, both the CRF and 5-HT systems 
when sufficiently activated will independently lead to anxiety responses. The 5-HT2AR 
selective antagonist M100907 itself also provoked marked reductions of open arm entries 
suggesting that M100907 could independently induce an anxiety-like response. As entries 
into the closed arm were observed, it was clear that the absolute failure to enter the open arm 
was not due to motor impairments, and instead it was likely that the reduced activity 
reflected an overall increase of anxiety. However, of particular significance, was the 
observation that the anxiety-provoking effects of CRF and DOI cotreatment were 
antagonized by M100907 pretreatment. Thus our observations indicated that cross-talk 
between CRF- and 5-HT-mediated signaling processes occured in the prefrontal cortex and 
that CRF sensitized 5-HT2-processes to promote stressor-like effects, such as anxiety35.
Based on our data, we propose a multistep mechanism whereby CRF peptide activation of 
CRFR1 enhances 5-HT2R signaling by increasing the availability of 5-HT2R at the surface 
of cells to be activated by agonist and to couple to the activation of phospholinositol 
phosphatase Cβ-mediated inositol phosphate formation (Supplemental Data Fig. 4). We 
found that agonist-activation of CRFR1 promoted the dynamin-dependent internalization of 
CRFR1 into the intracellular endosomal compartment of the cell and we found that 5-
HT2AR and 5-HT2CR were internalized to endosomes in a constitutive manner. Thus, 
following agonist treatment internalized CRFR1 facilitated the cell surface recycling of 5-
HT2R from endosomes resulting in increased 5-HT2R protein at the cell surface. The CRFR-
dependent enhancement of 5-HT2R signaling also required the interaction of PDZ domain 
containing proteins with both receptors, since the deletion of PDZ binding motifs in the 
carboxyl-terminal tail domains of either CRFR1, 5-HT2AR or 5-HT2CR prevented CRF-
mediated sensitization of 5-HT2R signaling. Interestingly, the activation of CRFR2, another 
CRFR expressed in the brain, did not sensitize 5-HT2AR signaling and consistent with this 
observation examination of the CRFR2 carboxyl-terminal tail revealed that the canonical 
PDZ binding motif was disrupted.
We found that sensitization of 5-HT2R signaling was dependent on receptor endocytosis as 
dynamin I-K44A expression could block this effect. This suggested that the internalization 
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of either the CRFR1 or the 5-HT2Rs was essential for sensitizing 5-HT2R signaling. Several 
lines of evidence suggest that it is the internalization of CRFR1 that is essential for this 
effect. First, both 5-HT2AR and 5-HT2CR are found to be predominantly intracellularly in 
neurons of the rat prefrontal cortex36,37. Second, in the present study we found that both 5-
HT2AR and 5-HT2CR were constitutively internalized in both HEK 293 cells and neurons, 
although cell surface expression of 5-HT2AR has been reported38-40. However, the 
mechanism underlying the observed constitutive endocytosis was unclear and may be 
consequence of the fact the serum used to culture cells may contain 5-HT. Independent of 
the mechanism by which 5-HT2R were internalized, we propose that it was the 
internalization and recycling of the CRFR1 that dynamically regulated the subcellular 
equilibrium of 5-HT2R resulting in the redistribution of 5-HT2R to the cell surface resulting 
in the sensitization of 5-HT2R signaling.
The CRFR1-mediated increases in 5-HT2AR signaling were also blocked by either the 
treatment of cells with monensin, which prevents the trafficking of intracellular vesicles or 
the overexpression of a dominant-negative Rab4-S28N mutant protein that blocked rapid 
recycling of GPCRs to the cell surface. Thus, CRFR1 sensitization of 5-HT2R signaling 
required increased 5-HT2R recycling and cell surface expression. The intracellular 
localization of 5-HT2R may prevent over-stimulation of serotonergic synapses. The 
regulated recruitment of this intracellular pool of 5-HT2R may function to promote altered 
post-synaptic signal adaptation to physiological stimuli, such as CRF peptide release in 
response to stress leading to the activation of CRFR1 in 5-HT2R expressing neurons of the 
prefrontal cortex. Such plasticity at serotonergic synapses may be akin to the alterations in 
AMPA receptor trafficking involved in synaptic plasticity associated with long term 
potentiation41.
We found that CRFR1-dependent alterations in 5-HT2R signaling required intact PDZ 
binding motifs at the carboxyl-terminal tails of both CRFR1 and 5-HT2Rs. Thus, these 
receptors may exist as components of a macromolecular protein complex via the recruitment 
of PDZ domain containing scaffold proteins. Although PDZ protein interactions have not 
been reported for the CRFR1, several PDZ domain-containing proteins have been 
demonstrated to interact with both 5-HT2Rs. Examples of PDZ domain containing proteins 
that interact with both 5-HT2R and 5-HT2CR include MAGI-2, MPP3, MUPP1, PSD-95 and 
SAP9730-34. Each of these PDZ domain containing proteins are comprised of multiple PDZ 
domains that would allow them to form complexes with more than one GPCR. PDZ domain 
containing proteins have also been demonstrated to regulate GPCR signaling, desensitization 
and trafficking. For example, PSD-95 inhibits β1AR internalization, but facilitates the 
association of the β1AR with NMDA receptors, whereas SAP97 interactions are involved in 
β1 AR recycling42. PSD-95 overexpression increases rat 5-HT2CR desensitization and 
facilitates both constitutive and agonist-induced rat 5-HT2CR internalization38. In contrast, 
PSD-95 interactions with 5-HT2AR leads to augmented 5-HT2AR signaling without altering 
the kinetics of 5-HT2A R desensitization30. PSD-95 is also required for proper dendritic 
targeting and expression of 5-HT2A and 5-HT2C receptors in vivo34. Thus, PDZ domain 
containing proteins may not only contribute to the formation of CRFR1/5-HT2R protein 
complexes, they may be involved in the regulation of the co-trafficking of the receptors 
between cellular compartments.
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In summary, the endocytosis and recycling of GPCRs plays an important role in regulating 
the desensitization and resensitization of GPCRs as well as modulating their signaling via G 
protein-independent signal transduction pathways43. Here, we identified an additional 
mechanism by which the endocytosis and recycling of one GPCR influenced the activity of 
a second GPCR by recruiting constitutively internalized receptors to the cell surface. As a 
consequence, we found that agonist-stimulated CRFR1 internalization resulted in the 
sensitization of 5-HT2R signaling by allowing the recruitment of internalized 5-HT2R to the 
plasma membrane. Our studies provide a novel biochemical mechanism to explain how 
CRFR1 activation sensitizes 5-HT2R-mediated anxiety behaviours in response to stress that 
is likely to be applicable to other receptor-mediated signaling pathways and behavioral 
responses.
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Refer to Web version on PubMed Central for supplementary material.
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The FLAG-tagged human (h) 5-HT2CR plasmid construct was generated by PCR and 
subcloned into pcDNA3.1 and the FLAG-tagged human (h) 5-HT2AR plasmid construct was 
previously described34. The FLAG-5-HT2CR-ΔSSV and HA-CRFR1-ΔTAV mutant 
receptors were constructed using the using the QuikChange™ site-directed mutagenesis kit 
(Stratagene). The HA-CRFR1 and GFP-Rab constructs were described previously29,44. The 
CRFR2 cDNA clone was the kind gift of Dr. Wylie Vale.
Cell Cuture and transfection
HEK 293 cells were maintained in Eagle’s minimal essential medium supplemented with 
10% fetal bovine serum and gentamicin (100 μg/ml). Cells were seeded on 100mm dishes at 
80-90% density one day before transfection. Transfection was carried using a modified 
calcium phosphate method as described previously47. After transfection (approximately 17 
hours), cells were washed with phosphate buffered saline (PBS), pooled and reseeded on 
appropriate dishes. Primary prefrontal cortical neurons were prepared from E18 CD1 mouse 
embryos as described previously29. Rat cortical neurons (R-cx-500, QBM cell science, 
Ottawa, Canada) were thawed and cultured for 6 days as suggested by manufacturers, then 
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transfected with 4 μg of plasmid DNA encoding each receptor using lipofectamine. The 
University of Western Ontario Animal Care Committee approved all animal protocols.
Inositol Phosphate Formation
Inositol phosphate formation in HEK 293 cells and mouse cortical neurons was determined 
by labeling cellular inositol lipids with 1 μCi/ml [3H] myo-inositol as previously 
described46. Cells were then preincubated in either the presence or absence of CRF peptide 
for 30 min at 37° C and then stimulated with increasing concentrations (0-10μM) of 5-HT 
for 30 min at 37° C. Total [3H] inositol phosphate was purified from cell extracts by anion 
exchange chromatography [3H] inositol phosphate formation was determined by liquid 
scintillation counting as previously described46. For inositol phosphate formation assay in 
brain slices, we utilized the protocol described by Conn and Sanders-Bush47 with minor 
modifications. Briefly, prefrontal cortex was isolated and cross-chopped (350 × 350 μm). 
Slices were suspended in Krebs Ringer Buffer (KRB) (108 mM NaCl 4.7 mM KCl, 1.2 mM 
MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, 10 mM Glucose) and 
incubated for 30 min at 37° C in a shaking bath under an atmosphere of O2/CO2 (95:5). 
Slices were then washed 3 times with 15 ml warm KRB and incubated with 5 μCi/ml [3H] 
myo-Inositol for 90 min (200 μl of gravity packed slices per ml of KRB). To remove excess 
radioactive inositol, slices were washed with 40 volumes of warm KRB containing 10 mM 
unlabeled myo-Inositol and allowed to settle under gravity. Buffer was aspirated off and 30 
μl of gravity packed slices were aliquoted into tubes containing 240μl of KRB containing 10 
mM LiCl, 10 μM pargyline and ascorbic acid (100 μM). Slices were incubated for 15 min at 
37° C. Following LiCl incubation, slices were preincubated in the presence or absence of 
500 nM CRF peptide for 45 min at 37° C (final volume = 270 μl). Slices were then 
stimulated with 5-HT for 45 min (final volume = 300 μl). The reaction was terminated by 
the addition of 3 volumes of chloroform/methanol (2:1, v/v) for 15 min at room temperature. 
One volume each of chloroform and HCl 0.15N was then added and the tubes were vortexed 
for 1 min. The phases were separated either by centrifugation at 1600 rpm for 5 min. Total 
inositol phosphate was purified from slice extracts by anion exchange chromatography as 
described above. Raw data was normalized for protein content which was measured in 
triplicate samples of prelabeled slices using the Bio-Rad Dc Protein Assay Kit following the 
manufacturer’s instructions.
cAMP Assay
Protocol was carried out as suggested by manufacturer. Briefly, HEK 293 cells transiently 
expressing FLAG-5-HT2AR and HA-CRFR1 were seeded into 96-well plate (10,000 cells/
well). Two days after transfection, cells were incubated in the absence or presence of 10 μM 
5-HT in induction buffer [HBSS, 500 μM isobutyl-1-methylxanthine (IBMX)] for 30 
minutes at 37°C. Cells were then incubated with increasing concentrations of CRF peptide 
for 30 minutes. Following stimulation, cells were solubilized with cAMP-Glo lysis buffer 
for 15 minutes with gently shaking at room temperature. Lysates were carefully transferred 
to a white opaque 96-well plate and cAMP-Glo Detection solution containing protein kinase 
A was added for 20 minutes at room temperature followed by addition of Kinase-Glo 
Reagent for 10 min. Luminescence was measured using a Victor Reader (Perkin-Elmer, 
Walthan, MA).
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Immunofluroescence was done as previously detailed on wt or 5-HT2A KO mice34. In brief, 
mice were transcardialy perfused with 4% paraformaldehyde in 1x PBS. Brains were then 
harvested and placed 12 h in 4% paraformaldehyde in 1x PBS at 4°C and then placed in 
30% sucrose in 1x PBS until they sank, then frozen on dry ice and stored at −80°C. Sections 
(30μm) were free-floating in 1x PBS (one per well in a 24-well plate) and then 
permeabilized with 0.4% Triton X100 in 1x PBS for 1 hour. PBS 1X/0.4% Triton X100 
containing 0.1% glycine, 0.1% lysine, 1% BSA and 1% normal donkey serum. Primary 
antibodies (anti 5-HT2A, rabbit polyclonal, Neuromics cat # RA24288 and anti CRFR1, goat 
polyclonal, Abcam cat # ab59023) were incubated in blocking buffer for 72 hours at 4°C. 
Sections were then washed five times in 1x PBS/0.4% triton (10 min each). Hoechst (2-5 
μg/ml) and secondary antibodies: donkey Alexa Fluor 555 conjugated anti-goat (1:500) and 
donkey Alexa Fluor 488 conjugated anti-rabbit antibodies (1:500) (Invitrogen) were diluted 
in blocking buffer and slices were incubated for 1 hour at RT. Sections were washed five 
times in 1x PBS/0.4% triton (10 min each). Sections were mounted on slides and visualized 
by Zeiss LSM-510 META multophoton laser scanning microscope with a Zeiss 25X NA 1.2 
oil immersion lens and appropriate filters.
Biotinylation of Cell Surface Receptor
HEK 293 cells transiently expressing wild-type and truncated FLAG-5-HT2AR and HA-
CRFR1 were seeded into 100 mm dishes and pre-incubated for 30 minutes in HBSS. Cells 
were then treated for 30 min with or without 500 nM CRF, washed twice with ice-cold 
HBSS and placed on ice for biotin labeling. Cell surface receptors were labeled on ice with 
biotin (1mg/ml) for 1 hour. Following labeling, cells were washed 3 times with 10 mM 
glycine and then 2 times with HBSS, lysed and equal amounts of total protein were 
incubated with neutravidin beads for 2 hours with rotation at 4°C. Beads were then washed 3 
times with lysis buffer and one time with PBS. Proteins were eluted from beads by addition 
of 50ul of SDS loading buffer. Samples were resolved by SDS-PAGE, transferred to 
nitrocellulose membrane and subsequently immunoblotted as described above with rabbit 
polyclonal FLAG antibody.
Surgical Procedure
Male CD-1 mice were obtained from Charles River Canada (St. Constant, Quebec) at 50-60 
days of age, and were acclimatized to the laboratory for approximately 30 days before 
serving as experimental subjects. Mice were housed four per cage, until the time of surgery, 
after which they were housed individually. The vivarium was maintained on a 12-h light/
dark cycle in a temperature (21°C) controlled room with food and water freely available. 
Mice were anesthetized using isoflurane and stereotaxic surgery (David Kopf Instruments 
Model 940) was performed to install a cannulae into the medial prefrontal cortex. A Guide 
cannulae (Plastics One In), situated according to the mouse atlas of Franklin and Paxinos48 
at Lateral= 0.32 mm, D/V= 2.25 mm, A/P= + 2.68 mm. A dummy cannula, was inserted 
flush with guide. Approximately 1 week after behavioral testing mice were perfused with 4 
% paraformaldehyde. Brains were subsequently sectioned at 14 microns and stained with 
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Cresyl violet for probe placement verification. Only the data from mice with correct probe 
placements were used in the analysis of the behavioral tests.
Drug Treatments
One week after surgical recovery animals were infused with 1.0 μl of CRF (1.5 μg) or 
vehicle (Phoenix Pharmaceuticals) over a 5 min period through an internal cannulae situated 
0.3 mm below the guide cannulae. Drug diffusion was permitted for 5 min, and then after a 
further 5 min period mice were injected intraperotineally with DOI (Sigma) at a dose of 0.15 
mg/kg or saline. Behavioral testing was conducted 15 min after the DOI treatment. In a 
second experiment the procedure was identical to that of the preceding study, except that 
mice were pretreated i.p. with either vehicle or 0.25 mg/kg of M100907 in a volume of 0.3 
ml immediately prior to the DOI treatment. As in the preceding study mice were then tested 
in the elevated plus maze test (n=6-8)/group. Once again, data were obtained from 
videotapes and the researcher was blind as to the treatments mice had received.
Behavioral Testing
In an initial test, mice were placed in a 45 × 45 cm open field, with an inner square of 21 × 
24 × 24 cm., for a 5 min period, during which the time to enter the center area, and the total 
time spent in the center portion of the arena was recorded. The plus maze test was then 
conducted 1 min after the open field assessment. Mice were individually placed in one of the 
enclosed arms of a plus-maze and the behavior of the animals was recorded over a 5 min 
period by a ceiling-mounted video camera. The amount of time spent in each of the arms, 
the number of arm entries (an arm entry was defined as all four of the paws being placed in 
an arm of the plus-maze). The elevated plus-maze had two arms enclosed by 21 cm high 
walls; whereas the remaining two arms were open (arms were 24.8 cm long × 7.7 cm wide). 
The maze was situated in a dimly lit room, such that the closed arms were darkened, 
whereas open arms were somewhat illuminated. All behavioural experiments were blinded. 
All experiments complied with the guidelines set by the Canadian Council on Animal Care 
and were approved by the Carleton University Animal Care Committee.
Data Analysis
The mean and the standard error of the mean were expressed for values obtained from the 
number of separate experiments indicated. Dose response data were analyzed using 
GraphPad Prism (GraphPad Software). Statistical significance was determined by analysis 
of variance and corrected for multinositol phosphatele comparisons. For behavioural testing 
data were analyzed by either a two factor (Drug infusion and DOI treatment) or three factor 
(Drug indusion, DOI treatment and M100907) analysis of variance (ANOVA), as 
appropriate, independently for each of the outcome measures. Follow-up tests were 
conducted by Bonferonni t tests corrected to maintain the α at 0.05.
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Effect of CRFR1 activation on 5-HT2R signaling.
Dose response curves for 5-HT-stimulated inositol phosphate (IP) formation in HEK 293 
cells pretreated with and without CRF (500 nM) for 30 min in cells transfected with (a) 
either FLAG-5-HT2AR and FLAG - 5-HT2cR alone, (b) FLAG-5-HT2AR and HA-CRFR1, 
or (c) FLAG-5-HT2cR and HA-CRFR1. (d) Basal and agonist-stimulated inositol formation 
in cells expressing FLAG-5-HT2cR alone, HA-CRFR1 alone, or expressing both FLAG-5-
HT2cR and HA-CRFR1. Cells were treated with 500 nM CRF with or without a subsequent 
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exposure to 10 μM 5-HT for 30 min. (e) Dose response curves for 5-HT stimulated inositol 
phosphate formation in HEK 293 cells transfected with FLAG-5-HT2AR and β2AR and 
pretreated with and without 100 μM isoproterenol (Iso) for 30 min. (f) Dose response curves 
for 5-HT stimulated inositol phosphate formation in HEK 293 cells transfected with 
FLAG-5-HT2AR and CRFR2 and pretreated with and without 500 nM CRF for 30 min. (g) 
Dose response curves for CRF-stimulated cAMP formation in HEK 293 cells transfected 
with FLAG-5-HT2AR and HA-CRFR1 and pretreated with and without 10 μM 5-HT for 30 
min. The data represent the mean ± S.E.M. for 3-6 individual experiments.
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Effect of CRFR1 activation on 5-HT2R signaling in neurons.
Shown are representative laser scanning confocal micrographs demonstrating the 
coexpression of endogenous (a) 5-HT2AR (green) and (b) CRFR1 (red) in 30 μm neuronal 
slice derived from prefrontal cortex of C57/BL6 mice. Neurons are also stained for (c) 
neuclei (Hoechst). (d) Shown is the colocalization of the 5-HT2AR and CRFR1 in a 
subpopulation of neurons (dashed circles). (e) Shown is a magnified view of 5-HT2AR and 
CRFR1 coloclization in a subpopulation of neurons (dashed circles) in dashed box in Fig. 
2d. Cortical layers are identified with roman numerals. Bar = 50 μm.
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Role of endocytosis in CRFR1-dependent augmentation of 5-HT2R signaling.
(a) Dose response curves for 5-HT stimulated inositol phosphate (IP) formation in HEK 293 
cells transfected with FLAG-5-HT2AR and HA-CRFR1 and pretreated with and without 500 
nM CRF for 30 min in the presence of dominant-negative dynamin I-K44A. The dose 
response curves represent the mean ± S.E.M. for 4 independent experiments. Shown are 
representative laser scanning confocal micrographs showing the distribution of (b) FLAG-5-
HT2AR and HA-CRFR1 and (c) FLAG-5-HT2CR and HA-CRFR1 in HEK 293 cells labeled 
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with FLAG and HA antibodies at 4°C and then warmed to 37°C for 30 min in the absence of 
agonist. (d) Shown are representative laser scanning confocal micrographs showing the 
distribution of FLAG-5-HT2AR and HA-CRFR1 labeled with FLAG and HA antibodies at 
4°C and warmed to 37°C for 30 min in the absence of agonist. (e) Shown are representative 
laser scanning confocal micrographs showing the distribution of FLAG-5-HT2AR and HA-
CRFR1 transfected into rat cortical neurons labeled with FLAG and HA antibodies at 4°C 
and treated with 500 nM CRF and warmed to 37°C for 30 min. (f) Shown are representative 
laser scanning confocal micrographs showing the distribution of FLAG-5-HT2AR and HA-
β2AR transfected into HEK 293 cells labeled with FLAG and HA antibodies at 4°C and 
treated with 100 μM Iso and warmed to 37°C for 30 min. Micrographs are representative 
images of multiple cells imaged on three independent occasions. Bar = 10 μm.
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Role of receptor recycling in CRF modulated 5-HT2R signaling.
(a) Dose response curves for 5-HT stimulated inositol phosphate (IP) formation in HEK 293 
cells transfected with FLAG-5-HT2AR and HA-CRFR1 and pretreated with and without 500 
nM CRF for 30 min following the pretreatment of cells with and without 100 μM monensin 
for 30 min. (b) Dose response curves for 5-HT stimulated inositol phosphate formation in 
HEK 293 cells with transfected FLAG-5-HT2AR, HA-CRFR1 and Rab4S8N and pretreated 
with and without 500 nM CRF for 30 min. (c) Dose response curves for 5-HT stimulated 
inositol phosphate formation in HEK 293 cells transfected with FLAG-5-HT2AR, HA-
CRFR1 and Rab11-S25N and pretreated with and without 500 nM CRF for 30 min. (d) 
Increase in cell surface 5-HT2AR localization following 30 min pretreatment of CRFR1 with 
500 nM CRF. The cell surface expression of the 5-HT2AR represents the mean ± S.E.M. for 
4 independent experiments. The full length blot is presented in Supplementary Fig. 5. * 
P<0.05 versus untreated control.
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Receptor determinants of CRF-dependent increases in 5-HT2R signaling.
(a) Shown is the change in cell surface 5-HT2AR and 5-HT2AR-ΔSCV localization 
following 30 min pretreatment of CRFR1 with 500 nM CRF as well as the change in cell 
surface 5-HT2AR localization following 30 min pretreatment of CRFR1-ΔTAV with 500 nM 
CRF. The cell surface expression of the 5-HT2AR represents the mean ± S.E.M. for 4 
independent experiments. *P<0.05 versus untreated control. (b) Dose response curves for 5-
HT stimulated inositol phosphate (IP) formation in HEK 293 cells transfected with FLAG-5-
HT2cR and either HA-CRFR1 or HA-CRFR1 lacking a PDZ domain binding motif (ΔTAV) 
pretreated with and without 500 nM CRF for 30 min. (c) Dose response curves for 5-HT 
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stimulated inositol phosphate formation in HEK 293 cells transfected with HA-CRFR1 and 
either FLAG-5-HT2CR or FLAG-5-HT2CR lacking a PDZ domain binding motif (ΔSSV) 
pretreated with and without 500 nM CRF for 30 min. (d) Dose response curves for 5-HT 
stimulated inositol phosphate formation in HEK 293 cells transfected with HA-CRFR1 and 
either FLAG-5-HT2AR or FLAG-5-HT2AR lacking a PDZ domain binding motif (ΔSCV) 
pretreated with and without 500 nM CRF for 30 min. (e) Dose response curves for 5-HT 
stimulated inositol phosphate formation in HEK 293 cells transfected with HA-CRFR1 and 
FLAG-5-HT2AR pretreated for 1 h with a Tat-fusion peptide corresponding to the last 10 
amino acid residues of the CRFR1 carboxyl-terminal tail and then treated with and without 
500 nM CRF for 30 min. Dose response curves represent the mean ± S.E.M. for 3-5 
independent experiments.
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Analysis of CRF pretreatment on 5-HT2R-mediated anxiety-related behaviours.
(a) Mean latencies for mice to enter the center square in a 5 min open field. (b) Mean 
latency to enter the open arms of the elevated plus maze. (c) The frequency of entries in to 
the open arms of the elevated plus maze. (d) The frequency of entries in to the closed arms 
of the elevated plus maze. (e) Time spent in the closed arms of the elevated plus maze. In all 
experiments, either vehicle or CRF (1.5 μg in 1 μl) was administered to the medial prefrontal 
cortex via a surgically implanted cannulae for 5 min and 5 min later mice were 
Magalhaes et al. Page 25













intraperotineally injected with vehicle or DOI (0.15 mg/kg) prior to behavioral testing. 9-10 
mice were used in each test group. P< 0.01 versus vehicle/vehicle treated control. Data 
represents mean ± SD. *P< 0.01 versus vehicle/vehicle treated control.
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Analysis of CRF pretreatment on 5-HT2R-mediated anxiety-related behaviours following 
M100907 treatment.
(a) Mean latency to enter the open arms of the elevated plus maze in a 5 min test period. (b) 
The frequency of entries in to the open arms of the elevated plus maze. (c) Time spent in the 
open arms of the elevated plus maze. (d) The frequency of entries in to the closed arms of 
the elevated plus maze. (e) Time spent in the closed arms of the elevated plus maze. In all 
experiments, either vehicle or CRF (1.5 μg in 1 μl) was administered to the medial prefrontal 
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cortex via a surgically implanted cannulae for 5 min and 5 min later mice were 
intraperotineally injected with vehicle or DOI (0.15 mg/kg) and mice were pretreated i.p. 
with either vehicle or 0.25 mg/kg of M100907 in a volume of 0.3 ml prior to DOI 
administration before behavioral testing. 6-8 mice were used in each test group. Data 
represents mean ± SD. *P< 0.05 versus respective vehicle control. ** P< 0.05 versus 
respective M100907 treatment. ϕP< 0.05 relative to M100907 and CRF treatment.
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